CN110636858B - 人抗脑信号蛋白4d抗体 - Google Patents

人抗脑信号蛋白4d抗体 Download PDF

Info

Publication number
CN110636858B
CN110636858B CN201880029632.7A CN201880029632A CN110636858B CN 110636858 B CN110636858 B CN 110636858B CN 201880029632 A CN201880029632 A CN 201880029632A CN 110636858 B CN110636858 B CN 110636858B
Authority
CN
China
Prior art keywords
antibody
antigen
binding fragment
fragment
sema4d
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880029632.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN110636858A (zh
Inventor
E·S·史密斯
A·康尼尔森
M·G·M·斯科瑞文斯
M·帕里斯
M·造德尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vaccinex Inc
Original Assignee
Vaccinex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vaccinex Inc filed Critical Vaccinex Inc
Publication of CN110636858A publication Critical patent/CN110636858A/zh
Application granted granted Critical
Publication of CN110636858B publication Critical patent/CN110636858B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201880029632.7A 2017-05-05 2018-05-04 人抗脑信号蛋白4d抗体 Active CN110636858B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762501981P 2017-05-05 2017-05-05
US62/501,981 2017-05-05
PCT/US2018/031263 WO2018204895A1 (en) 2017-05-05 2018-05-04 Human anti-semaphorin 4d antibody

Publications (2)

Publication Number Publication Date
CN110636858A CN110636858A (zh) 2019-12-31
CN110636858B true CN110636858B (zh) 2024-03-19

Family

ID=64016767

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880029632.7A Active CN110636858B (zh) 2017-05-05 2018-05-04 人抗脑信号蛋白4d抗体

Country Status (14)

Country Link
US (3) US11427634B2 (enExample)
EP (1) EP3618865A4 (enExample)
JP (3) JP7246320B2 (enExample)
KR (1) KR102680924B1 (enExample)
CN (1) CN110636858B (enExample)
AU (2) AU2018261947B2 (enExample)
BR (1) BR112019023138A2 (enExample)
CA (1) CA3061963A1 (enExample)
IL (1) IL270244B2 (enExample)
MX (2) MX2019013110A (enExample)
NZ (1) NZ758300A (enExample)
SG (1) SG11201909466RA (enExample)
WO (1) WO2018204895A1 (enExample)
ZA (1) ZA201907148B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9708601B2 (en) 2012-04-26 2017-07-18 Vaccinex, Inc. Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus
BR112018071686A2 (pt) 2016-04-22 2019-02-19 Vaccinex, Inc. exibição de proteínas integrais de membrana em vírions extracelulares envelopados de poxvírus
WO2018026715A1 (en) 2016-08-02 2018-02-08 Vaccinex, Inc. Improved methods for producing polynucleotide libraries in vaccinia virus/eukaryotic cells
CN110636858B (zh) * 2017-05-05 2024-03-19 瓦西尼斯公司 人抗脑信号蛋白4d抗体
US20210032322A1 (en) 2019-08-01 2021-02-04 Vaccinex, Inc. Combined inhibition of semaphorin-4d and tgf-beta and compositions therefor
CN117597360A (zh) * 2020-06-25 2024-02-23 瓦西尼斯公司 脑信号蛋白-4d结合分子在rett综合征治疗中的应用
CA3231551A1 (en) 2021-09-27 2023-03-30 Maurice Zauderer Predictive outcome profiling for use of an anti-semaphorin-4d binding molecule to treat neurodegenerative disorders
US20230331863A1 (en) 2022-02-13 2023-10-19 Vaccinex, Inc. Combination therapy with semaphorin-4d blockade and htt-lowering agent for treatment of huntington's disease
KR102875105B1 (ko) * 2023-04-03 2025-10-21 주식회사 사이알바이오 재조합 세마포린 4d 차단항체를 유효성분으로 포함하는 쇼그렌 증후군 예방 또는 치료용 약학 조성물
CN117924494B (zh) * 2024-01-23 2025-02-25 首都医科大学附属北京积水潭医院 特异性结合sema4d的抗原结合蛋白及其应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013148854A1 (en) * 2012-03-28 2013-10-03 Vaccinex, Inc. Anti-sema4d antibodies and epitopes
CN103945868A (zh) * 2011-05-13 2014-07-23 国立大学法人东京医科齿科大学 骨生成促进剂
CN104127862A (zh) * 2014-08-14 2014-11-05 武汉大学 Semaphorin 4D在预防及治疗骨代谢性疾病中的应用
CN104619341A (zh) * 2012-05-11 2015-05-13 瓦西尼斯公司 脑信号蛋白-4d结合分子在促进中风后的神经发生中的用途
CN106029093A (zh) * 2013-10-21 2016-10-12 瓦西尼斯公司 脑信号蛋白-4d结合分子治疗神经变性疾病的用途

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ201918A (en) 1981-09-18 1987-04-30 Genentech Inc N-terminal methionyl analogues of bovine growth hormone
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
EP0216846B2 (en) 1985-04-01 1995-04-26 Celltech Limited Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
AU631802B2 (en) 1988-06-14 1992-12-10 Cetus Oncology Corporation Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
ZA902949B (en) 1989-05-05 1992-02-26 Res Dev Foundation A novel antibody delivery system for biological response modifiers
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
WO1991014438A1 (en) 1990-03-20 1991-10-03 The Trustees Of Columbia University In The City Of New York Chimeric antibodies with receptor binding ligands in place of their constant region
ATE218889T1 (de) 1990-11-09 2002-06-15 Stephen D Gillies Cytokine immunokonjugate
FR2686087A1 (fr) 1992-01-13 1993-07-16 Inst Nat Sante Rech Med Nouvel antigene lymphocytaire, anticorps correspondant et leurs applications.
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US20020102208A1 (en) 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
AU2001297872B2 (en) 2000-11-17 2006-11-09 University Of Rochester In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells
WO2002096948A2 (en) 2001-01-29 2002-12-05 Idec Pharmaceuticals Corporation Engineered tetravalent antibodies and methods of use
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
EP1442749A1 (en) 2003-01-31 2004-08-04 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of anti-CD100 antibodies for the treatment and the diagnosis of inflammatory disorder affecting the central nervous system
HRP20140172T1 (hr) 2006-05-30 2014-03-28 Genentech, Inc. Protutijela i imunokonjugati kao i njihove uporabe
ES2396220T3 (es) 2006-08-11 2013-02-20 Ono Pharmaceutical Co., Ltd. Anticuerpos monoclonales frente al factor 1 derivado del estroma (SDF-1)
EP2069404B1 (en) 2007-02-14 2011-01-05 Vaccinex, Inc. Humanized anti-cd100 antibodies
FI20075278A0 (fi) 2007-04-20 2007-04-20 Biotie Therapies Corp Uudet täysin ihmisperäiset anti-VAP-1 monoklonaaliset vasta-aineet
EP2157937B1 (en) 2007-06-04 2017-03-22 Sequent Medical, Inc. Devices for treatment of vascular defects
MX2011002837A (es) 2008-09-19 2011-07-29 Medimmune Llc Anticuerpos dirigidos al ligando tipo delta 4 (dll4) y usos de los mismos.
NO2427212T3 (enExample) 2009-05-08 2018-01-20
CN104168956A (zh) * 2011-10-11 2014-11-26 瓦西尼斯公司 臂板蛋白-4d结合分子用于调节血脑屏障渗透性的用途
US9708601B2 (en) 2012-04-26 2017-07-18 Vaccinex, Inc. Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus
BR112015032690B1 (pt) 2013-06-25 2020-03-10 Vaccinex, Inc. Uso de moléculas inibidoras de semaforina-4d em combinação com uma terapia imunomoduladora para inibir o crescimento tumoral e metástase
NZ630881A (en) 2013-10-10 2016-03-31 Vaccinex Inc Use of semaphorin-4d binding molecules for treatment of atherosclerosis
AU2015367684A1 (en) * 2014-12-15 2017-07-06 Galapagos Nv Antibodies for IL-17C
CN110636858B (zh) * 2017-05-05 2024-03-19 瓦西尼斯公司 人抗脑信号蛋白4d抗体
CN117597360A (zh) * 2020-06-25 2024-02-23 瓦西尼斯公司 脑信号蛋白-4d结合分子在rett综合征治疗中的应用

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103945868A (zh) * 2011-05-13 2014-07-23 国立大学法人东京医科齿科大学 骨生成促进剂
WO2013148854A1 (en) * 2012-03-28 2013-10-03 Vaccinex, Inc. Anti-sema4d antibodies and epitopes
CN104619341A (zh) * 2012-05-11 2015-05-13 瓦西尼斯公司 脑信号蛋白-4d结合分子在促进中风后的神经发生中的用途
CN106029093A (zh) * 2013-10-21 2016-10-12 瓦西尼斯公司 脑信号蛋白-4d结合分子治疗神经变性疾病的用途
CN104127862A (zh) * 2014-08-14 2014-11-05 武汉大学 Semaphorin 4D在预防及治疗骨代谢性疾病中的应用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Antibody Blockade of Semaphorin 4D Promotes Immune Infiltration into Tumor and Enhances Response to Other Immunomodulatory Therapies;Elizabeth E Evans等;《Cancer Immunol Res》;第3卷(第6期);第689-701页 *
Generation and preclinical characterization of an antibody specific for SEMA4D;Terrence L Fisher等;《MAbs》;第8卷(第1期);第150-162页 *
SEMA4D compromises blood-brain barrier, activates microglia, and inhibits remyelination in neurodegenerative disease;Ernest S Smith等;《Neurobiol Dis》;第73卷;第254-268页 *

Also Published As

Publication number Publication date
SG11201909466RA (en) 2019-11-28
US11427634B2 (en) 2022-08-30
IL270244A (en) 2019-12-31
ZA201907148B (en) 2025-06-25
EP3618865A1 (en) 2020-03-11
JP2020518248A (ja) 2020-06-25
MX2023003519A (es) 2023-04-19
JP7460819B2 (ja) 2024-04-02
CA3061963A1 (en) 2018-11-08
US20240309091A1 (en) 2024-09-19
CN110636858A (zh) 2019-12-31
JP2024081694A (ja) 2024-06-18
KR102680924B1 (ko) 2024-07-02
MX2019013110A (es) 2019-12-16
JP2023075271A (ja) 2023-05-30
WO2018204895A1 (en) 2018-11-08
RU2019131732A3 (enExample) 2021-09-28
RU2019131732A (ru) 2021-06-07
BR112019023138A2 (pt) 2020-07-28
AU2018261947B2 (en) 2024-06-13
US20220356249A1 (en) 2022-11-10
KR20200004324A (ko) 2020-01-13
AU2018261947A1 (en) 2019-11-07
AU2024204752A1 (en) 2024-08-01
US20210032329A1 (en) 2021-02-04
EP3618865A4 (en) 2021-05-05
NZ758300A (en) 2025-11-28
JP7246320B2 (ja) 2023-03-27
IL270244B1 (en) 2024-09-01
US12006365B2 (en) 2024-06-11
IL270244B2 (en) 2025-01-01

Similar Documents

Publication Publication Date Title
US12006364B2 (en) Anti-CD100 antibodies and methods for using the same
CN110636858B (zh) 人抗脑信号蛋白4d抗体
RU2776443C2 (ru) Антитела человека против семафорина 4d

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant